MENTAL HEALTH RESOURCES Resources for LGBTQ+ Individuals Grappling With Homelessness We explore shelter, housing, crisis, and mental health resources for LGBTQ+ people facing homelessness
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease [PMID: 17186181] Laboratory literature summary: Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)
Long-term follow-up: Evaluate its impact on the risk of metabolic syndrome and cardiovascular diseases
At 36 weeks, the mean weight loss is 3.2% with 0.5 mg, 7.9% with 4 mg (initial dose 2 mg), 10.4% with 4 mg (no escalation), 16.8% with 8 mg (initial dose 2 mg), 16.3% with 8 mg (initial dose 4 mg), and 16.9% with 12 mg (initial dose 2 mg), versus 3.0% with placebo and 2.0% with 1.5 mg dulaglutide (106)
Customs in the EU, UK, and Australia may flag research peptide shipments